LAKEWOOD-AMEDEX BIOTHERAPEUTICS INC.

LABT ·Healthcare, Drug Manufacturers - General, United States
Financial Statements Cash Flow Statement
Annual Quarterly

Cash Flow Statement

Line Item Jun 2026 Mar 2026 Jun 2025 Mar 2025
Operating Activities
Net Income $-3.8M $-923.3K $-655.9K $-539.6K
Depreciation & Amortization
Depreciation $1.2K $1.2K $1.2K $1.2K
Amortization
Stock-Based Compensation $46.2K $53.8K
Net Cash from Operating Activities $-2.1M $-349.7K $-508.6K $-404.1K
Investing Activities
Capital Expenditures
Business Acquisitions
Net Cash from Investing Activities
Financing Activities
Dividends Paid
Stock Repurchases
Net Cash from Financing Activities $125.0K $200.0K
Net Change in Cash
Free Cash Flow